Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRR013
MIFTS: 36

Prurigo Nodularis

Categories: Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prurigo Nodularis

About this section

MalaCards integrated aliases for Prurigo Nodularis:

Name: Prurigo Nodularis 52 54 71 32
Nodular Prurigo 52

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 L28.1
UMLS 71 C0263353
Sources

Summaries for Prurigo Nodularis

About this section
NIH Rare Diseases : 52 Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules ) to form on the skin. The itching (pruritus ) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing. In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis ), lymphoma , HIV infection , severe anemia , or kidney disease . The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place. Diagnosis of the disease is based on observing signs such as extremely itchy skin with the formation of nodules. In some cases, a skin biopsy is used to confirm the diagnosis. Treatment may include corticosteroid creams , oral medications, cryotherapy , or photochemotherapy .

MalaCards based summary : Prurigo Nodularis, also known as nodular prurigo, is related to anhidrosis and dermatitis, atopic. An important gene associated with Prurigo Nodularis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Nalbuphine and Serlopitant have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and thyroid.

Wikipedia : 74 Prurigo nodularis (PN), also known as nodular prurigo, is a skin disease characterised by pruritic... more...

Sources

Related Diseases for Prurigo Nodularis

About this section

Diseases related to Prurigo Nodularis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 anhidrosis 30.0 NGFR NGF
2 dermatitis, atopic 29.8 TAC1 RNASE3 NGFR NGF
3 neuroma 29.7 SEMA3A NGF
4 amyloidosis, primary localized cutaneous, 1 11.4
5 epidermolysis bullosa pruriginosa 11.4
6 amyloidosis, primary localized cutaneous, 2 11.4
7 amyloidosis, primary localized cutaneous, 3 11.4
8 skin disease 10.7
9 dermatitis 10.7
10 neuropathy 10.6
11 peripheral nervous system disease 10.6
12 neurodermatitis 10.5
13 bullous pemphigoid 10.5
14 keratosis 10.4
15 lichen planus 10.4
16 ige responsiveness, atopic 10.4
17 vitiligo-associated multiple autoimmune disease susceptibility 6 10.4
18 vitiligo-associated multiple autoimmune disease susceptibility 1 10.4
19 lymphoma 10.4
20 contact dermatitis 10.4
21 keratoacanthoma 10.4
22 chronic kidney disease 10.4
23 hypereosinophilic syndrome 10.4
24 lymphoma, hodgkin, classic 10.3
25 human immunodeficiency virus type 1 10.3
26 exanthem 10.3
27 allergic hypersensitivity disease 10.3
28 hepatitis 10.3
29 allergic contact dermatitis 10.3
30 pustulosis of palm and sole 10.3
31 uremia 10.3
32 scabies 10.3
33 herpes zoster 10.3
34 vasculitis 10.3
35 psoriasis 10.3
36 erythermalgia, primary 10.1
37 hashimoto thyroiditis 10.1
38 systemic lupus erythematosus 10.1
39 pernicious anemia 10.1
40 sarcoidosis 1 10.1
41 thrombocytopenic purpura, autoimmune 10.1
42 celiac disease 1 10.1
43 immune deficiency disease 10.1
44 myeloma, multiple 10.1
45 proteasome-associated autoinflammatory syndrome 1 10.1
46 dermatitis herpetiformis, familial 10.1
47 becker nevus syndrome 10.1
48 lymphoma, non-hodgkin, familial 10.1
49 pulmonary disease, chronic obstructive 10.1
50 nasopharyngeal carcinoma 10.1

Graphical network of the top 20 diseases related to Prurigo Nodularis:



Diseases related to Prurigo Nodularis
Sources

Symptoms & Phenotypes for Prurigo Nodularis

About this section
Sources

Drugs & Therapeutics for Prurigo Nodularis

About this section

Drugs for Prurigo Nodularis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nalbuphine Approved Phase 2, Phase 3 20594-83-6 5360630 5311304
2 Serlopitant Investigational Phase 3 860642-69-9
3 Narcotics Phase 2, Phase 3
4 Analgesics, Opioid Phase 2, Phase 3
5 Central Nervous System Depressants Phase 2, Phase 3
6 Analgesics Phase 2, Phase 3
7 Neurotransmitter Agents Phase 3
8 neurokinin A Phase 3
9 Neurokinin-1 Receptor Antagonists Phase 3
10
Substance P Phase 3 33507-63-0 44359816
11 Pharmaceutical Solutions Phase 3
12 Immunologic Factors Phase 3
13 Calcineurin Inhibitors Phase 3
14 Antibodies, Monoclonal Phase 3
15 Antibodies Phase 3
16 Immunoglobulins Phase 3
17
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
18
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
19
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
20
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
21
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
22 Hydrocortisone hemisuccinate Phase 2
23 Hydrocortisone-17-butyrate Phase 2
24 Hydrocortisone 17-butyrate 21-propionate Phase 2
25 Antipruritics Phase 1, Phase 2
26 Anti-Infective Agents Phase 1, Phase 2
27 Anti-Bacterial Agents Phase 1, Phase 2
28 Anti-Inflammatory Agents Phase 1, Phase 2
29 Analgesics, Non-Narcotic Phase 1, Phase 2
30 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
31 Angiogenesis Inhibitors Phase 1, Phase 2
32 Antirheumatic Agents Phase 1, Phase 2
33 Immunosuppressive Agents Phase 1, Phase 2
34 Dermatologic Agents Phase 1, Phase 2
35
Citalopram Approved 59729-33-8 2771
36
leucovorin Approved 58-05-9 6006 143
37
Dapsone Approved, Investigational 80-08-0 2955
38
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
39 Serotonin Uptake Inhibitors
40 Antiparkinson Agents
41 Psychotropic Drugs
42 Serotonin Agents
43 Muscarinic Antagonists
44 Cholinergic Agents
45 Autonomic Agents
46 Cholinergic Antagonists
47 Antidepressive Agents
48 Parasympatholytics
49 Vitamin B Complex
50 Folic Acid Antagonists

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174419 Phase 2, Phase 3 nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID
2 An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174432 Phase 2, Phase 3 nalbuphine HCl ER 90 mg BID;nalbuphine HCl ER 120 mg BID;nalbuphine HCl ER 180 mg BID
3 A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) Recruiting NCT03497975 Phase 2, Phase 3 Nalbuphine ER Tablets
4 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Recruiting NCT04183335 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
5 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Active, not recruiting NCT03677401 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
6 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Active, not recruiting NCT03546816 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
7 A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Not yet recruiting NCT04204616 Phase 3 Nemolizumab
8 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Not yet recruiting NCT04202679 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
9 A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN) Completed NCT03181503 Phase 2 CD14152 Dose A;CD14152 placebo
10 A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis Completed NCT02196324 Phase 2 serlopitant;Placebo
11 An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis Completed NCT00869089 Phase 2 CC-10004
12 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2 Pimecrolimus;Hydrocortisone;Pimecrolimus
13 A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis Recruiting NCT03816891 Phase 2 KPL-716;Placebo
14 Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Recruiting NCT03576287 Phase 1, Phase 2 Apremilast Oral Product
15 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519 citalopram (cipralex)
16 A Double-blind, Randomized, Parallel-group, Side-by-side Single-center Study Comparing a Topical Steroid / Vehicle Combination to a Topical Steroid / Topical Dapsone Combination in Patients With Lichen Simplex Chronicus and/or Prurigo Nodularis Unknown status NCT01870050 Dapsone gel - verum

Search NIH Clinical Center for Prurigo Nodularis

Sources

Genetic Tests for Prurigo Nodularis

About this section
Sources

Anatomical Context for Prurigo Nodularis

About this section

MalaCards organs/tissues related to Prurigo Nodularis:

40
Skin, Kidney, Thyroid, Tonsil, T Cells, Brain, Liver
Sources

Publications for Prurigo Nodularis

About this section

Articles related to Prurigo Nodularis:

(show top 50) (show all 525)
# Title Authors PMID Year
1
Psychiatric disorders and pruritus. 61 52
28511824 2017
2
Treatment of prurigo nodularis with lenalidomide. 61 52
27891738 2017
3
Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. 54 61
11875644 2002
4
Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. 54 61
10994770 2000
5
Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. 54 61
9609137 1998
6
Eosinophilic cationic protein (ECP) in skin disorders. 54 61
1685831 1991
7
Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. 61
32017045 2020
8
Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. 61
31421126 2020
9
Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. 61
31529718 2020
10
Diagnostic and treatment algorithm for chronic nodular prurigo. 61
31310842 2020
11
Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned. 61
31734938 2020
12
Chronic prurigo: A retrospective study of 168 cases. 61
31907978 2020
13
Analysis of real-world treatment patterns in patients with prurigo nodularis. 61
31521720 2020
14
Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis. 61
31900001 2020
15
Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis. 61
31517666 2020
16
Dupilumab for prurigo nodularis: Case series and review of the literature. 61
31917498 2020
17
Cannabinoids for the Treatment of Chronic Pruritus: A Review. 61
31987788 2020
18
Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis. 61
31936197 2020
19
Efficacy of dupilumab in prurigo nodularis in elderly patient. 61
31856368 2020
20
An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis. 61
31132160 2020
21
A patient with concurrent prurigo nodularis and squamous cell carcinomas of keratoacanthoma type: The role of aprepitant in diagnostic clarity. 61
31956685 2020
22
Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. 61
31568781 2019
23
Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation. 61
31442331 2019
24
Sleep quality among adult patients with chronic dermatoses. 61
31997991 2019
25
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. 61
31693426 2019
26
Fibreglass dermatitis in a caravan manufacturer manifesting as prurigo nodularis. 61
31177543 2019
27
Association between prurigo nodularis and malignancy in middle-aged adults. 61
30954580 2019
28
Paraneoplastic eczematous eruption associated with Hodgkin's lymphoma. 61
31656430 2019
29
Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis 61
31603635 2019
30
Eosinophilic dermatoses. 61
31562692 2019
31
Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. 61
31442084 2019
32
Dupilumab Treatment for Prurigo Nodularis and Pruritis 61
31524352 2019
33
Prurigo nodularis as a sweat gland/duct-related disorder: resolution associated with restoration of sweating disturbance. 61
31152230 2019
34
Racial and Gender Differences in the Presentation of Pruritus. 61
31569651 2019
35
Diagnostic Workup and Evaluation of Patients with Prurigo Nodularis. 61
31561504 2019
36
Racial differences in dermatologic conditions associated with HIV: A cross-sectional study of 4679 patients in an urban tertiary care center. 61
31499147 2019
37
Role of Dermoscopy in the Diagnosis of Hypertrophic Lichen Planus and Prurigo Nodularis. 61
31543526 2019
38
[Pruritus in systemic diseases : Common and rare etiologies]. 61
31243493 2019
39
Dramatic improvement of generalized prurigo nodularis with dupilumab. 61
30893496 2019
40
Inpatient Burden of Prurigo Nodularis in the United States. 61
31405223 2019
41
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. 61
31272246 2019
42
IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis. 61
31476318 2019
43
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? 61
31145194 2019
44
Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. 61
30894279 2019
45
Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis. 61
30809683 2019
46
Recalcitrant prurigo nodularis treated successfully with dupilumab. 61
31192991 2019
47
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). 61
30653242 2019
48
Corticosteroid-resistant prurigo nodularis: a rare syringotropic variant associated with hypohidrosis. 61
30827950 2019
49
Allergic contact dermatitis caused by chloramphenicol with prurigo nodularis-like spreading. 61
30485440 2019
50
Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1. 61
30588658 2019
Sources

Variations for Prurigo Nodularis

About this section
Sources

Expression for Prurigo Nodularis

About this section
Search GEO for disease gene expression data for Prurigo Nodularis.
Sources

Pathways for Prurigo Nodularis

About this section

Pathways related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Phospholipase-C Pathway 63
Show member pathways
 12.52 SEMA3A NGFR NGF
2
p70S6K Signaling 63
Show member pathways
 12.49 SEMA3A NGFR NGF
3
NF-KappaB Family Pathway 63
Show member pathways
 12.05 SEMA3A NGFR NGF
4
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.64 NGFR NGF
5
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 11.54 SEMA3A NGFR NGF
6
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.27 NGFR NGF
7
p75(NTR)-mediated signaling 1
Show member pathways
 11.19 NGFR NGF
8
Neurotrophic factor-mediated Trk receptor signaling 1
Show member pathways
 11.11 NGFR NGF
9
Guidance Cues and Growth Cone Motility 63
10.87 SEMA3A NGFR NGF
10
14-3-3 and Regulation of BAD Activity 63
10.46 NGFR NGF
Sources

GO Terms for Prurigo Nodularis

About this section

Cellular components related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 TAC1 SEMA3A RNASE3 NGF
2 axon GO:0030424 9.13 TAC1 SEMA3A NGF
3 extracellular region GO:0005576 9.02 TAC1 SEMA3A RNASE3 NGFR NGF

Biological processes related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.37 NGFR NGF
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.32 NGFR NGF
3 positive regulation of axonogenesis GO:0050772 9.26 NGFR NGF
4 neurotrophin TRK receptor signaling pathway GO:0048011 9.16 NGFR NGF
5 nerve development GO:0021675 8.96 SEMA3A NGF
6 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 8.62 NGFR NGF
Sources

Sources for Prurigo Nodularis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....